Top Page
Pro Medicus Limited
(Sydney:PME)
Pro Medicus Limited (PME) vs. iShares MSCI Australia ETF (EWA)
Pro Medicus Limited Business Overview & Revenue Model
Pro Medicus Limited Earnings Call Summary
Pro Medicus Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 212.98M | 212.91M | 161.43M | 124.90M | 93.46M | 67.88M |
| Gross Profit | 169.16M | 212.60M | 122.24M | 92.36M | 92.94M | 46.66M |
| EBITDA | 170.62M | 164.85M | 120.69M | 91.69M | 69.64M | 49.53M |
| Net Income | 115.22M | 115.22M | 82.79M | 60.65M | 44.44M | 30.85M |
Balance Sheet | ||||||
| Total Assets | 338.70M | 338.70M | 257.43M | 202.13M | 157.05M | 125.57M |
| Cash, Cash Equivalents and Short-Term Investments | 209.19M | 209.19M | 154.89M | 121.50M | 90.55M | 61.82M |
| Total Debt | 2.25M | 2.25M | 2.07M | 1.85M | 2.28M | 2.62M |
| Total Liabilities | 81.74M | 81.74M | 69.70M | 63.36M | 55.32M | 43.89M |
| Stockholders Equity | 256.96M | 256.96M | 187.73M | 138.78M | 101.73M | 81.68M |
Cash Flow | ||||||
| Free Cash Flow | 118.43M | 103.95M | 80.08M | 58.33M | 53.20M | 31.33M |
| Operating Cash Flow | 118.87M | 111.33M | 86.78M | 64.77M | 62.23M | 39.02M |
| Investing Cash Flow | -14.12M | -6.58M | -78.07M | -9.79M | -17.56M | -27.40M |
| Financing Cash Flow | -57.62M | -57.62M | -39.84M | -27.53M | -23.31M | -14.05M |
Pro Medicus Limited Technical Analysis
Pro Medicus Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $21.96B | 190.61 | 50.70% | 0.24% | 31.88% | 39.10% | |
62 Neutral | AU$154.44M | 95.83 | 1.89% | ― | 10.06% | ― | |
54 Neutral | AU$144.51M | -23.84 | -12.35% | ― | 15.99% | 22.05% | |
52 Neutral | AU$21.84M | -12.11 | -17.05% | ― | 28.91% | -1050.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$59.04M | -6.45 | -8647.54% | ― | 25.98% | 22.10% |
Pro Medicus Limited Corporate Events
Pro Medicus Limited has disclosed a small increase in the shareholding of director Anthony Barry Hall, who acquired 2,270 additional ordinary shares in an on-market trade at $220.31 per share. Following the transaction, Hall’s total relevant interest in Pro Medicus has risen to 24,148,520 ordinary shares held across various personal, superannuation and family trust structures, underscoring continued insider confidence and maintaining his significant stake in the company.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a minor change in the shareholding of Director Sam Aaron Hupert, who has increased his direct interest in the company through an on‑market purchase of 2,250 ordinary shares at $221.99 per share. The transaction, executed via ALLHC Pty Ltd as trustee for the Sam Hupert Family Trust, lifts Hupert’s total holding to 24,192,160 ordinary shares, slightly reinforcing the director’s equity stake and signalling continued alignment of management interests with those of shareholders.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus director Anthony Barry Hall has marginally increased his stake in the healthcare imaging software group through an on-market purchase of additional ordinary shares. Hall acquired 2,250 Pro Medicus shares on 22 December 2025 at $221.90 per share via Research Corporation Pty Ltd as trustee for the Anthony Hall Family Trust, lifting his total holding to 24,146,250 shares across various entities, a move that signals ongoing confidence in the company but does not materially alter its capital structure.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has disclosed a change in the holdings of director Sam Aaron Hupert, who has increased his direct interest in the company through an on-market purchase of 2,250 ordinary shares at $221.45 per share via ALLHC Pty Ltd as trustee for the Sam Hupert Family Trust. Following the transaction, Hupert’s total holding has risen marginally to 24,189,910 ordinary shares across his personal, superannuation and family trust structures, signalling ongoing alignment of the director’s financial interests with those of shareholders but without materially altering the company’s ownership structure.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has provided an updated notification to the ASX regarding its on-market share buy-back of ordinary fully paid shares under code PME. The company reported that it had repurchased a total of 45,324 shares prior to the previous trading day and a further 3,200 shares on the previous day, as part of an ongoing buy-back program first notified in April 2025, with this update dated 19 December 2025, indicating continued capital management activity that may support earnings per share and signal confidence in the company’s valuation to investors.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program, with a recent purchase of 2,100 ordinary fully paid securities, bringing the total bought back to 43,224. This buy-back initiative reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update on its ongoing share buy-back program, with a total of 1,060 ordinary fully paid securities bought back on the previous day, adding to the 42,164 securities bought back prior. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially increase shareholder value, reflecting a proactive approach to managing its financial resources.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid shares. As of December 12, 2025, the company has bought back a total of 42,164 shares, including 1,025 shares acquired on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update on its ongoing on-market buy-back program, with a total of 39,001 securities bought back before the previous day and an additional 2,138 securities acquired on the previous day. This buy-back initiative reflects the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing buy-back program, with a total of 4,000 ordinary fully paid securities bought back on the previous day, adding to a cumulative total of 35,001 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has addressed recent speculation regarding a data breach involving Visage Imaging. The company confirmed that an unauthorized access incident occurred in July 2025, affecting a single email inbox, but no client systems or patient data were compromised. The breach was contained, and external cybersecurity experts were engaged. While some personal information of approximately 100 employees might have been accessed, no financial loss or operational impact was reported. Pro Medicus has informed affected individuals and relevant authorities, ensuring compliance with legal obligations.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has secured a $25 million, 7-year contract with BayCare, a leading healthcare system in Florida, to implement its Visage 7 Open Archive in the cloud. This deal extends their existing contract to a full-stack solution, enhancing Pro Medicus’s expansion into the North American IDN market and offering potential financial upside through a transaction-based model.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited held its Annual General Meeting on November 24, 2025, where all resolutions on the agenda were successfully carried. Key resolutions included the approval of the remuneration report and the re-election of board members, indicating strong shareholder support and stability in the company’s governance.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited reported a successful year both operationally and financially, attributing its achievements to its robust business model and the dedication of its staff. The company secured several new contracts, including its largest to date with Trinity Health, and continues to expand its product offerings through strategic acquisitions and licensing, strengthening its market position in North America and Germany.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has signed three new contracts valued at a minimum of A$29 million, expanding its presence in the healthcare imaging market. These contracts, which are cloud-based and transaction-oriented, involve a pediatric hospital, a cancer center, and a regional healthcare provider, highlighting the company’s adaptability across various segments. This development increases the company’s total contract value for the first half of FY26 to A$273 million, reinforcing its strong market position and future growth potential.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has secured a significant 5-year, A$44M contract with Advanced Radiology Management, a prominent private radiology group. This agreement involves implementing the cloud-based Visage 7 Enterprise Imaging Platform, which aims to enhance diagnostic interpretation efficiency. The rollout is set to begin immediately, with the platform expected to go live by late Q2 2026. This contract underscores Pro Medicus’s growing influence in the North American healthcare IT market and addresses the increasing demand for efficient radiology solutions amid a global shortage of radiologists.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$290.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced a daily update on its ongoing on-market buy-back program, with a total of 3,915 ordinary fully paid securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in its financial health.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$320.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of November 14, 2025, the company has repurchased a total of 31,086 ordinary fully paid securities, including 3,904 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$320.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing buy-back program, detailing the acquisition of 3,865 ordinary fully paid securities on the previous day, bringing the total bought back to 23,317. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$320.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update on its ongoing on-market buy-back program, with a recent acquisition of 3,924 ordinary fully paid securities. This buy-back strategy is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value, reflecting a strategic move to optimize financial performance and market positioning.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$283.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of November 11, 2025, the company has repurchased a total of 19,393 ordinary fully paid securities, including 3,902 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$283.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of the latest notification, the company has repurchased a total of 11,559 ordinary fully paid securities, with 3,911 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$283.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced its Annual General Meeting (AGM) scheduled for November 24, 2025, which will be conducted as a hybrid meeting. Shareholders can participate in person or online, with provisions made for voting and asking questions through a dedicated portal. This meeting is crucial for stakeholders to engage with the company’s board and discuss resolutions, reflecting Pro Medicus’s commitment to transparency and shareholder engagement.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$317.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has secured a 5-year, A$10 million contract to implement its Visage 7 Enterprise Imaging Platform at University Hospital Heidelberg and the German Cancer Research Institute, among other associated hospitals. This deal expands Pro Medicus’s presence in the European market, replacing and consolidating existing legacy systems to enhance diagnostic and research capabilities, thereby supporting cutting-edge medical research and patient care.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited announced that it is not affected by the recently announced US tariffs on pharmaceuticals, as the company does not engage in the production or sale of pharmaceutical products. This clarification ensures that Pro Medicus’s operations remain unaffected by these tariffs, maintaining its focus on providing cutting-edge medical imaging solutions without any direct implications from the pharmaceutical industry tariffs.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$333.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.